Christopher Chavez, PhD (INTP-T)

Christopher Chavez, PhD (INTP-T), has a diverse work experience in the field of molecular biology and synthetic biology. Christopher currently serves as the Vice President of Molecular Biology at Visgenx, Inc since May 2020 and previously held the position of Senior Scientist at the same company from October 2019 to May 2020. Prior to this, they worked at Beeline Therapeutics as the CTO Synthetic Biology and CAR Treg Cell Engineer from April 2019 to October 2019, where they utilized CRISPR/Cas9 technology to engineer primary Tregs for specificity and function. Christopher also has experience at Adicet Bio, Inc where they worked as a Senior Scientist in Synthetic Biology, focusing on gamma-delta CAR-T and Retro-Viral Vector engineering from August 2017 to April 2019. Before that, they worked at Adverum Biotechnologies, Inc. as a Senior Scientist in Synthetic Biology, AAV Vector Engineering, and Gene Therapy from January 2014 to July 2017. Christopher was involved in the development of AAV vectors for gene therapy applications and genome engineering using CRISPR/Cas9 system and phage integrases. Christopher also worked as a Research Scientist in Gene Therapy at System Biosciences from June 2012 to December 2013 and held multiple roles at Stanford University School of Medicine, including Research Scientist and Postdoctoral Researcher from January 2007 to May 2012.

Christopher Chavez, PhD (INTP-T) pursued their education in a chronological manner, with a strong focus on genetics and molecular biology. Christopher began their academic journey at Humboldt State University from 1993 to 1997, where they obtained a Bachelor of Science (B.S.) degree in Molecular Biology. Following this, they went on to the University of California, Santa Cruz, where they furthered their knowledge and expertise by completing a Ph.D. in Genetics from 1997 to 2005. Finally, Dr. Chavez pursued a Postdoctoral education at Stanford University School of Medicine, specializing in Gene/Cell Therapy from 2007 to 2012.